FILING ANALYSIS · THURSDAY, NOVEMBER 5
Shattuck Labs, Inc. STTK — 8-K: Results of Operations and Financial Condition
neutral
The company reported its Q3 2026 financial results and provided updates on its clinical trials, including the initiation of a Phase 2b trial for SL-325 in Crohn's disease and plans to initiate a Phase 2 trial in hidradenitis suppurativa, but no quantified surprises were disclosed.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →